Overview
| Generic Names: | DLV; SPP |
|---|---|
| Trade Names: | Bhap Der; Rescriptor |
| PharmGKB Accession Id: | PA449223 |
Description
A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. PubChem (source: Drug Bank)
Indication
For the treatment of HIV-1 infection in combination with appropriate antiretroviral agents when therapy is warranted (source: Drug Bank)
ATC Therapeutic Category
- J05AG:Non-nucleoside reverse transcriptase inhibitors
Pharmacology, Interactions, and Contraindications
Mechanism Of Action
Delavirdine binds directly to viral reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by disrupting the enzyme's catalytic site. (source: Drug Bank)
Pharmacology
Delavirdine is a non-nucleoside reverse transcriptase inhibitor (nNRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Delavirdine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of Delavirdine does not compete with template or nucleoside triphosphates. HIV-2 RT and eukaryotic DNA polymerases (such as human DNA polymerases alpha, beta, or sigma) are not inhibited by Delavirdine. (source: Drug Bank)
Food Interactions
Take without regard to meals. (source: Drug Bank)
Absorption, Distribution, Metabolism, Elimination & Toxicity
Biotransformation
Hepatic (source: Drug Bank)
Protein Binding
98% (source: Drug Bank)
Absorption
Rapidly absorbed (source: Drug Bank)
Toxicity
Major toxicity of delavirdine is rash and should be advised to promptly notify their physician should rash occur. The majority of rashes associated with delavirdine occur within 1 to 3 weeks after initiating treatment with delavirdine. The rash normally resolves in 3 to 14 days and may be treated symptomatically while therapy with delavirdine is continued. Any patient experiencing severe rash or rash accompanied by symptoms such as fever, blistering, oral lesions, conjunctivitis, swelling, muscle or joint aches should discontinue medication and consult a physician. (source: Drug Bank)
Isomeric SMILES Code:
CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C (source: Drug Bank)
The following genes are in curated knowledge about this drug.
| Gene | Relationship | Evidence | |
|---|---|---|---|
|
CYP2D6 |
|
Publications |
A list of non-curated publications that mention this drug along with other genes is available.
Drug Targets
The following drugs are in curated knowledge about this drug.
| Drug | Relationship | Evidence | |
|---|---|---|---|
|
tamoxifen |
|
Publications |
A list of non-curated publications that mention this drug along with other drugs is available.
Drug Interactions
| Drug | Description | |
|---|---|---|
| alprazolam |
|
The antiviral agent increases the effect and toxicity of benzodiazepine (source: Drug Bank) |
| amprenavir |
|
Decreased levels of delavirdine with increased levels of amprenavir (source: Drug Bank) |
| astemizole |
|
Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank) |
| atorvastatin |
|
The NNRT inhibitor increases the effect and toxicity of the statin (source: Drug Bank) |
| calcium |
|
The antiacid decreases the effect of delavirdine (source: Drug Bank) |
| carbamazepine |
|
The anticonvulsant decreases the effect of delavirdine (source: Drug Bank) |
| cisapride |
|
Increased risk of cardiotoxicity adn arrhythmias (source: Drug Bank) |
| ergonovine |
|
The antiretroviral agent may increase the ergot derivative toxicity (source: Drug Bank) |
| fosamprenavir |
|
Decreased levels of delavirdine with increased levels of amprenavir (source: Drug Bank) |
| indinavir |
|
Increases the effect of indinavir (source: Drug Bank) |
| lovastatin |
|
The NNRT inhibitor increases the effect and toxicity of the statin (source: Drug Bank) |
| magnesium |
|
The antiacid decreases the effect of delavirdine (source: Drug Bank) |
| magnesium oxide |
|
The antiacid decreases the effect of delavirdine (source: Drug Bank) |
| methylergonovine |
|
The antiretroviral agent may increase the ergot derivative toxicity (source: Drug Bank) |
| methylphenobarbital |
|
The anticonvulsant decreases the effect of delavirdine (source: Drug Bank) |
| midazolam |
|
The antiviral agent increases the effect and toxicity of benzodiazepine (source: Drug Bank) |
| phenobarbital |
|
The anticonvulsant decreases the effect of delavirdine (source: Drug Bank) |
| phenytoin |
|
The anticonvulsant decreases the effect of delavirdine (source: Drug Bank) |
| rifabutin |
|
Rifabutin decreases the effect of delavirdine (source: Drug Bank) |
| rifampin |
|
Rifampin decreases the effect of delavirdine (source: Drug Bank) |
| ritonavir |
|
Increases the effect of ritonavir (source: Drug Bank) |
| saquinavir |
|
Increases the effect of saquinavir and hepatic toxicity (source: Drug Bank) |
| simvastatin |
|
The NNRT inhibitor increases the effect and toxicity of the statin (source: Drug Bank) |
| terfenadine |
|
Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank) |
| triazolam |
|
The antiviral agent increases the effect and toxicity of benzodiazepine (source: Drug Bank) |
Non-Curated Information
A list of non-curated publications that mention this drug along with other diseases is available.
LinkOuts
Common Searches
Search PubMed
Search Medline Plus
Search PubChem
Search CTD
Non-Curated Publications
A list of non-curated publications that mention this drug is available.